.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX24_Surufatinib.Surufatinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX24_Surufatinib.Surufatinib| name: | Surufatinib |
| ATC code: | L01EX24 | route: | oral |
| n-compartments | 2 |
Surufatinib is an oral small molecule tyrosine kinase inhibitor targeting VEGFR, FGFR1, and CSF-1R. It is developed for the treatment of neuroendocrine tumors (NETs) and has received approval in China for the treatment of non-pancreatic neuroendocrine tumors.
Pharmacokinetics reported for adult patients with advanced solid tumors, typically Asian (Chinese) individuals. Data most extensively reported for the oral administration of surufatinib at steady state.